NanoString Technologies Inc. and Fluidigm Corporation Settle Lawsuits

Published: Oct 02, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE, Oct. 1, 2013 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG) and Fluidigm Corporation (Nasdaq:FLDM) have agreed to settle lawsuits filed by Fluidigm in the United States and Singapore. In the U.S. case, Fluidigm charged NanoString with false advertising, unfair competition, and unlawful trade practices based on a comparison study of NanoString's Single Cell Gene Expression Assay on the nCounterĀ® Analysis System with the Single Cell Gene Expression capabilities of Fluidigm's BioMarkā„¢ HD system. The lawsuit in Singapore was based on the same study and contained similar allegations. NanoString denies the allegations in both lawsuits.

Help employers find you! Check out all the jobs and post your resume.

Back to news